HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.

Abstract
Use of tamoxifen for treatment and prevention of breast cancer is becoming increasingly common. Tamoxifen has been associated with increased risk of endometrial carcinoma, although the exact mechanism of action is unknown. The aim of our study was to seek a possible correlation between endometrial carcinoma, tamoxifen exposure and MSI, PTEN, beta-catenin and K-ras abnormalities. A group of 18 patients with endometrial carcinoma following treatment with tamoxifen were selected. A control group included 15 patients with endometrial carcinoma and associated ovarian hyperthecosis and one patient with endometrial carcinoma and adult granulosa cell tumor of the ovary, chosen because both conditions are associated with increased production of estrogen and increased risk of endometrial carcinoma development. The second control group included 27 randomly selected consecutive patients with endometrial carcinoma without identifiable associated conditions. Immunostaining for beta-catenin was performed on all cases; DNA was extracted and amplified by PCR with primers for beta-catenin, K-ras and PTEN genes. BAT-25 and BAT-26 were analyzed to assess for MSI. There were 16 endometrioid endometrial carcinomas, one mixed carcinoma and one clear cell carcinoma among patients in the tamoxifen group. All patients with ovarian hyperthecosis and adult granulosa cell tumor had endometrioid endometrial carcinoma. In the random control group, there were 26 endometrioid endometrial carcinomas and one carcinosarcoma. Immunohistochemical and mutational analysis for beta-catenin showed abnormalities in 4/11 (36%) and 3/10 (30%) informative cases in the tamoxifen group; 7/16 (44%) and 4/15 (27%) informative cases, respectively in the ovarian hyperthecosis group and 1/27 random control cases (4%) (P<0.05). Patients with tamoxifen exposure had more K-ras mutations and fewer PTEN mutations and MSI as opposed to controls, but the results were not statistically significant. In conclusion, there was a direct relationship between tamoxifen exposure and overexpression of beta-catenin oncoprotein, which is known to play a major role in the pathogenesis of estrogen-driven, type I endometrial adenocarcinoma.
AuthorsJulia Turbiner, Gema Moreno-Bueno, Sonika Dahiya, Carolina Sánchez-Estevez, David Hardisson, Jaime Prat, Esther Oliva, José Palacios
JournalModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (Mod Pathol) Vol. 21 Issue 8 Pg. 925-36 (Aug 2008) ISSN: 1530-0285 [Electronic] United States
PMID18500270 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Biomarkers, Tumor
  • CTNNB1 protein, human
  • Neoplasm Proteins
  • beta Catenin
  • Tamoxifen
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Proto-Oncogene Proteins p21(ras)
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal (adverse effects)
  • Biomarkers, Tumor (metabolism)
  • Carcinoma, Endometrioid (chemically induced, genetics, pathology)
  • Endometrial Neoplasms (chemically induced, genetics, pathology)
  • Female
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Microsatellite Instability
  • Middle Aged
  • Neoplasm Proteins (genetics, metabolism)
  • Neoplasm Staging
  • PTEN Phosphohydrolase (genetics, metabolism)
  • Proto-Oncogene Proteins p21(ras) (genetics, metabolism)
  • Survival Rate
  • Tamoxifen (adverse effects)
  • beta Catenin (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: